Approval · Notice of Compliance 12205 · 2011
PEGETRON: Notice of Compliance 12205
Issued March 22, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12205
- Date
- March 22, 2011
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Antiviral agent plus biological response modifier
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PEGETRON | 02246026 | Cancelled Post Market |
| PEGETRON | 02246027 | Cancelled Post Market |
| PEGETRON | 02246028 | Cancelled Post Market |
| PEGETRON | 02246029 | Cancelled Post Market |
| PEGETRON | 02246030 | Cancelled Post Market |
| PEGETRON (REDIPEN) | 02254573 | — |
| PEGETRON (REDIPEN) | 02254581 | Cancelled Post Market |
| PEGETRON (REDIPEN) | 02254603 | Cancelled Post Market |
| PEGETRON (REDIPEN) | 02254638 | Cancelled Post Market |
| PEGETRON (REDIPEN) | 02254646 | Cancelled Post Market |
Medicinal ingredients
- PEGINTERFERON ALFA-2B 50 MCG per 0.5ML
- RIBAVIRIN 200 MG per CAP
- PEGINTERFERON ALFA-2B 80 MCG per 0.5ML
- PEGINTERFERON ALFA-2B 100 MCG per 0.5ML
- PEGINTERFERON ALFA-2B 120 MCG per 0.5ML
- PEGINTERFERON ALFA-2B 150 MCG per 0.5ML